Pharmaceutical GMP training built by a practicing, CPGP-certified GMP consultant — covering 21 CFR Parts 210 and 211, API cGMP under ICH Q7, validation, laboratory controls, and data integrity. Delivered on-site at your facility or as live virtual instructor-led sessions, with role-based tracks for production, QA/QC, laboratory, and leadership teams.
Your instructor holds ASQ's Certified Pharmaceutical GMP Professional credential — the exam-verified pharma-GMP qualification.
Modules are built from real audits, real 483 remediations, and real inspection experience — anonymized into lessons.
Production, QA/QC, laboratory, and leadership each get content matched to 21 CFR 211.25's "as it relates to their function."
Workshops at your facility, live virtual instructor-led sessions, or custom programs built around your quality system.
Pharmaceutical GMP training is not optional professional development — it is a regulatory requirement with your company's name on it. 21 CFR 211.25 requires that each person engaged in the manufacture, processing, packing, or holding of a drug product have the "education, training, and experience, or any combination thereof" to perform their assigned functions. It goes further: training must cover current good manufacturing practice as it relates to the employee's functions, must be conducted by qualified individuals, and must occur "on a continuing basis." One initial session at onboarding does not satisfy the regulation.
FDA investigators treat training as a window into the whole quality system. During an inspection, they pull training records, compare them against job functions, and probe whether operators actually understand the procedures they signed off on. Training deficiencies are a recurring theme in FDA Form 483 observations — sometimes cited directly under 211.25, and just as often lurking underneath other citations: a batch record error, a deviation handled incorrectly, an aseptic technique lapse. When the same mistake keeps appearing across operators, "inadequate training" is where the root-cause analysis lands.
Effective training is therefore inspection readiness. A workforce that understands why the batch record demands contemporaneous entries, why the cleaning validation limits exist, and why data integrity controls apply to everyone — not just the lab — makes fewer errors, writes better documentation, and answers investigator questions with confidence instead of panic. That is the practical difference between training that checks a compliance box and training that prevents 483 observations.
Every program at GMP Training Institute is built by a consultant who hosts inspections and remediates findings for real pharmaceutical manufacturers across 200+ client engagements. The examples in the slides are drawn from actual audit and inspection experience — anonymized, but real. Your team learns what investigators actually look for, because the instructor has sat across the table from them.
Programs are assembled from these core modules and scoped to your products, your processes, and your audit history. Mix and match, or run the full curriculum.
The architecture of FDA drug GMP: the quality unit and its authority, personnel requirements, buildings and equipment, materials control, production and process controls, packaging and labeling, and records. The foundation module every pharmaceutical employee needs.
GMP for active pharmaceutical ingredient manufacturing under ICH Q7: where GMP begins in the synthesis, intermediates and mother liquors, impurity profiles, and how Q7 expectations map to — and diverge from — finished drug product cGMP.
FDA's lifecycle approach: Stage 1 process design, Stage 2 process performance qualification, Stage 3 continued process verification. What a defensible validation package looks like, and where investigators find the gaps.
Residue limits and their scientific rationale, worst-case product selection, sampling methods (swab and rinse), analytical method suitability, and maintaining the validated state on shared equipment.
Stability study design under 211.166 and ICH Q1 expectations: protocol elements, storage conditions, bracketing and matrixing, out-of-specification and out-of-trend results, and using stability data to defend expiration dating.
Subpart I laboratory controls, OOS investigations, and the ALCOA+ data integrity principles FDA expects across paper and electronic records — audit trails, access controls, and the habits that make data trustworthy.
Complaint files under 211.198: intake, triage, investigation depth, the link to adverse event reporting and field alert obligations, and how complaint trends feed CAPA and annual product review.
The 211.180(e) annual review of records: what to evaluate (batches, complaints, deviations, stability, returns), how to trend it, and how to turn the APR from a paperwork exercise into a genuine process-improvement tool.
Need broader coverage across documentation, CAPA, and environmental monitoring? See the full cGMP training course catalog.
21 CFR 211.25 requires training in GMP "as it relates to the employee's functions." A line operator and a QC chemist should not sit through the same slides. Each track carries the same regulatory backbone with depth where the role needs it.
For operators, line leads, and supervisors: batch record execution and good documentation practices, line clearance, in-process controls, deviation recognition and reporting, gowning and hygiene, and equipment use and cleaning. Heavy on scenarios — what to do when the process does something the batch record did not anticipate.
For the quality unit: batch record review and disposition, deviation and OOS investigations, CAPA effectiveness, change control, supplier qualification, and the quality unit's non-delegable responsibilities under 211.22. Includes how investigators evaluate the quality unit's independence and authority.
For QC analysts and lab management: laboratory controls under Subpart I, analytical method validation and verification, reference standards, OOS/OOT investigations under FDA's guidance, stability testing operations, and data integrity in chromatography data systems and LIMS.
For site and executive leadership: what the regulation expects of management, quality culture and its inspection footprint, quality metrics that actually predict trouble, resourcing the quality unit, and how leadership behavior shows up in 483s and warning letters. Short, direct, and built for decision-makers.
Anyone can put "GMP trainer" on a slide deck. When you are choosing who trains your pharmaceutical workforce, ask one question: what independently verifies this person's pharmaceutical GMP expertise?
The Certified Pharmaceutical GMP Professional (CPGP) is ASQ's answer. It is not a general quality credential — it is an examination specifically on pharmaceutical GMP: the regulations, the quality systems, the laboratory and production controls, and how they are applied in practice. It exists precisely so that companies can distinguish practitioners who have proven pharmaceutical GMP mastery from generalists who have not.
Your instructor, Jared Clark, holds the CPGP — alongside CQA (Certified Quality Auditor) and CMQ-OE (Certified Manager of Quality/Organizational Excellence) from ASQ, RAC (Regulatory Affairs Certification) from RAPS, and JD, MBA, and PMP credentials. The RAC and JD add the regulatory "why" behind every requirement; the consulting practice adds the "how it actually plays out in an inspection." Most institutional courses can offer neither.
At your facility, using your SOPs and batch records as the raw material. Best for onboarding whole teams, pre-approval inspection prep, and post-483 remediation training.
Instructor-led over video — fully interactive, with Q&A and the same attendance and assessment documentation. Ideal for multi-site quality teams. Online training details →
Annual training plans, refresher curricula, and role-based tracks designed around your product portfolio, your quality system, and your inspection history.
Every session produces the documentation an FDA investigator will ask to see: attendance records, content summaries, and assessments. And when training surfaces a systems problem — a validation gap, a data integrity weakness — the same instructor can help you fix it through Certify Consulting, the consulting practice behind the Institute.
1. Scoping. Every engagement starts with a conversation about your operation: dosage forms and processes, whether you make finished drug products or APIs, team size and roles, your inspection history, and any deadlines driving the request — a pre-approval inspection on the calendar, a 483 response commitment, or an annual training plan coming due. If you have recent 483 observations or internal audit findings, they become the spine of the curriculum, because your training should target your actual failure modes.
2. Curriculum design. Modules are selected and tailored to your products and procedures. Where it strengthens the training, your own SOPs and blank batch records become the exercise material — operators practice good documentation on the forms they will actually sign, not generic worksheets.
3. Delivery. On-site at your facility or live over video, always instructor-led and interactive. Sessions are built around scenarios and questions, because adults learn GMP from cases — a data integrity finding, an OOS investigation gone wrong — far better than from regulation recitals.
4. Documentation and follow-up. You receive the complete training record package: attendance, content outline, and assessment results, ready for your training files and the next investigator who asks. Where the sessions surface systemic gaps, you get a candid summary of what we saw — and, if you want help fixing it, the consulting practice behind the Institute is a phone call away. Start the scoping conversation →
Jared Clark — JD, MBA, PMP, CMQ-OE, CQA, CPGP, RAC
Principal Consultant at Certify Consulting and holder of ASQ's Certified Pharmaceutical GMP Professional credential. Jared doesn't just teach pharmaceutical GMP — he implements it, with 200+ client engagements spanning drug, supplement, cosmetics, and food manufacturing. His legal training (JD) and RAC credential supply the regulatory "why" that makes the "how" stick with trainees.
The FDA regulations that govern drug manufacturing — 21 CFR Parts 210 and 211 — including the quality unit's responsibilities, personnel qualification, documentation and batch records, production and process controls, laboratory controls, stability, complaint handling, and annual product review. API manufacturers add cGMP under ICH Q7. Good programs tune the depth of each topic to the trainee's role.
Yes. 21 CFR 211.25 requires that each person engaged in drug manufacturing have the education, training, and experience to perform their assigned functions — including cGMP training conducted by qualified individuals "on a continuing basis." Investigators routinely review training records, and inadequate training is a recurring 483 theme.
Yes, in emphasis. FDA applies ICH Q7 as its cGMP expectation for active pharmaceutical ingredients, which differs from Part 211 in areas like where GMP begins in the synthesis, handling of intermediates and mother liquors, and impurity control. Our API module teaches Q7's structure and where it diverges from finished-product cGMP.
It depends on scope. A role-focused refresher can run a half day; cGMP fundamentals for new production staff typically runs one to two days; multi-module programs covering validation, laboratory controls, and data integrity are scheduled as a series. Every program is scoped to your team and compliance deadlines — tell us about yours.
CPGP is ASQ's Certified Pharmaceutical GMP Professional — an exam specifically on pharmaceutical GMP regulations and their application, not general quality knowledge. It gives you an independent, verifiable answer to "what qualifies this person to teach pharmaceutical GMP?" Your instructor holds the CPGP alongside CQA, CMQ-OE, RAC, JD, MBA, and PMP.
Tell us your products, team size, and compliance deadline. We'll design a 21 CFR 210/211 training program around your operations — and document every minute of it.